Skip to main content
. 2019 Jun 30;24(2):116–123. doi: 10.6065/apem.2019.24.2.116

Fig. 3.

Fig. 3.

Comparison of PAH, MPH, AH, and changes in subjects with central precocious puberty by type of treatment, expressed as (A) height, (B) SDS, and (C) PAH SDS for the first 3 years of gonadotropin-releasing hormone agonist (GnRHa) treatment. Group A, GnRHa alone group; group B, combined GnRHa/GH group; PAH, predicted adult height; MPH, midparental height; AH, adult height; SDS, standard deviation score. *P<0.001 vs. PAH or PAH SDS at start of GnRHa treatment. ***P<0.001 between the GnRHa group and the GnRHa plus GH group.